[1] 蔡文婷. 血清hs-CRP、Hcy、Cys-C水平与2型糖尿病周围神经病变的相关性[J]. 川北医学院学报,2022,37(7):924-927. DOI:10.3969/j.issn.1005-3697.2022.07.024.
[2] 曹洁琼,裴晓艳,胡红艳,等. 血清纤维蛋白胶凝素-3水平与2型糖尿病并发周围神经病变关系的研究[J]. 中华全科医学,2022,20(4):570-573. DOI:10.16766/j.cnki.issn.1674- 4152.002402.
[3] Zhang Y, Jin D, Duan Y, et al. Efficacy of Mudan granule (combined with methylcobalamin) on type 2 diabetic peripheral neuropathy: study protocol for a double-blind, randomized, placebo-controlled, parallel-arm, multi-center trial[J].Front Pharmacol,2021,12:676503. DOI:10.3389/fphar.2021.676503.
[4] 王艳华,李成,鄢碧珠. GA/HbA1c比值与2型糖尿病周围神经病变相关性研究[J]. 中国实用神经疾病杂志,2020,23(10):829-832. DOI:10.12083/SYSJ.2020.10.173.
[5] Toloza DC, Zequera M, Castro G. COP analysis in type 2 diabetics with peripheral diabetic neuropathy: (open data may contribute with prognosis and intervention in early stages to reduce a risk of falling)[J]. IFMBE Proceedings,2020,2(1):74. DOI:10.1007/978-3-030-30636-6_55.
[6] 向鹏月,马玉婷,吴秋霞,等. 2型糖尿病周围神经病变患者血清IMA、HbA1c水平变化及其临床意义[J]. 卒中与神经疾病,2019,26(3):342-345. DOI:10.3969/j.issn.1007- 0478.2019.03.021.
[7] Zaidan HK, Mohamed AH, Al-saadi AH. The role of extracellular superoxide dismutase (Ec-SOD) gene polymorphism in motor neuron damage of type 2 diabetic peripheral neuropathy patients of Babylon Province-Iraq[J]. Indian Journal of Public Health Research and Development,2019,10(10):2746. DOI:10.5958/0976-5506.2019.03284.4.
[8] Dixit S, Maiya A, Shastry BA. Effects of aerobic exercise on vibration perception threshold in type 2 diabetic peripheral neuropathy population using 3-sites method: single-blind randomized controlled trial[J].Altern Ther Health Med,2019,25(2):36-41.
[9] 罗一青,李娜,圈启芳,等. 老年2型糖尿病伴周围神经病变患者IL-1β 、HCY 、Cys-C 、HbA1c水平研究[J]. 国际检验医学杂志,2018,39(12):1425-1428. DOI:10.3969/j.issn. 1673-4130.2018.12.005.
[10] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):4-67. DOI:10.3760/cma.j.issn.1674-5809.2018.01.003.
[11] Simoneau A, Monlun M, Poupon P, et al. Comment on Jaiswalet al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care 2017;40:1226-1232[J]. Diabetes Care,2018,41(3):e35-e36.DOI:10.2337/dc17-2175.
[12] Jaiswal M, Divers J, Pop-Busui R, et al. Response to comment on Jaiswalet al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care 2017;40:1226-1232[J]. Diabetes Care,2018,41(3):e37. DOI:10.2337/dci17-0058.
[13] Parsa TA, Hosseini SRA, Bije N, et al. The study of the effect of a 16-week program of resistance-aerobic training on BDNF, HbA1c, pain, and Michigan neuropathy score among type 2 diabetic patients with peripheral neuropathy[J]. Journal of Diabetes and Metabolism,2018,9(11):1-8. DOI:10.4172/2155-6156.1000811.
[14] Rahman MT, Mohiuddin AS, Sharif MM, et al. Comparison of cross sectional areas of median nerve in type 2 diabetic patients with peripheral neuropathy with healthy adult subjects measured by 2 D-B mode high resolution ultrasonography[J]. BIRDEM Medical Journal,2018,8(1):47-51. DOI:10.3329/birdem.v8i1.35039.
[15] Gong YY, Peng HY. Correlation analysis of epicardial adipose tissue thickness, C-reactive protein, interleukin-6, visfatin, juxtaposed with another zinc finger protein 1, and type 2 diabetic macroangiopathy[J]. Lipids Health Dis,2021,20(1):25. DOI:10.1186/s12944-021-01451-7.
[16] Zhou X, Yang MX, Xu J, et al. Study on the expression of CD14+ CD16+ monocytes and VEGF in peripheral blood of patients with type 2 diabetes mellitus and diabetic macroangiopathy[J].Int J Diabetes Dev Ctries, 2020, 40(prepublish):1-6. DOI:10.1007/s13410-020-00809-4.
[17] Liu Y, Li X, Zhu Y, et al. Subclinical hypothyroidism contributes to poor glycemic control in patients with type 2 diabetes mellitus, and ellagic acid attenuates methimazole-induced abnormal glucose metabolism in mice model[J]. J Food Biochem,2021,45(6):e13753. DOI:10.1111/jfbc.13753.
[18] Allam MA, Nassar YA, Shabana HS, et al. Prevalence and clinical significance of subclinical hypothyroidism in diabetic peripheral neuropathy[J].Int J Gen Med,2021,14:7755-7761. DOI:10.2147/IJGM.S337779.
[19] Fan J, Pan Q, Gao Q, et al. TSH combined with TSHR aggravates diabetic peripheral neuropathy by promoting oxidative stress and apoptosis in Schwann cells[J].Oxid Med Cell Longev,2021,2021:2482453. DOI:10.1155/2021/2482453.
[20] Huang X, Zhang X, Zhou X, et al. Prevalence of thyroid dysfunction in a Chinese population with different glucose intolerance status: a community-based cross-sectional study[J].Diabetes Metab Syndr Obes,2020,13:4361-4368. DOI:10.2147/DMSO.S271328.
[21] Vujosevic S, Aldington SJ, Silva P, et al. Screening for diabetic retinopathy: new perspectives and challenges[J].Lancet Diabetes Endocrinol,2020,8(4):337-347. DOI:10.1016/S2213-8587(19)30411-5.
[22] Simó-Servat O, Hernández C, Simó R. Diabetic retinopathy in the context of patients with diabetes[J].Ophthalmic Res,2019,62(4):211-217. DOI:10.1159/000499541.
[23] Vásquez KA, Valverde EM, Aguilar DV, et al. Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination[J].Dement Neuropsychol,2019,13(1):78-81. DOI:10.1590/1980-57642018dn13-010008.
[24] Matveeva MV, Samoilova YG, Zhukova NG, et al. Rare genetic markers of cognitive impairment in diabetes mellitus[J]. Zh Nevrol Psikhiatr Im S S Korsakova,2019,119(2):76-79. DOI:10.17116/jnevro201911902176.
[25] Maiese K. Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways[J]. Expert Rev Clin Pharmacol,2020,13(1):23-34. DOI:10.1080/17512433.2020.1698288.
[26] Calviño-Sampedro C, Gomez-Tourino I, Cordero OJ, et al. Naturally presented HLA class I-restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes[J].FASEB J,2019,33(5):6390-6401. DOI:10.1096/fj.201802270R.
[27] McIntosh EC, Nation DA. Importance of treatment status in links between type 2 diabetes and Alzheimer's disease[J].Diabetes Care,2019,42(5):972-979. DOI:10.2337/dc18-1399.
[28] Ward R, Li W, Abdul Y, et al. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia[J].Pharmacol Res,2019,142:237-250. DOI:10.1016/j.phrs.2019.01.035.
[29] Biessels GJ, Whitmer RA. Cognitive dysfunction in diabetes: how to implement emerging guidelines[J].Diabetologia,2020,63(1):3-9. DOI:10.1007/s00125-019- 04977-9.
[30] Srikanth V, Sinclair AJ, Hill-Briggs F, et al. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities[J].Lancet Diabetes Endocrinol,2020,8(6):535-545. DOI:10.1016/S2213-8587(20)30118-2.
|